ReviewJournal of thrombosis and thrombolysis2026
Advancing cancer therapeutics: new perspectives on mechanisms, regulatory and policy challenges, and innovative multi-modality strategies for the early detection of cardiotoxicity.
Review in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Thrombosis: focus on molecular mechanisms, biomarkers and cardio-oncology.Journal of thrombosis and thrombolysis · 2026Article
- Thrombosis: focus on molecular mechanisms, biomarkers and cardio-oncology.Journal of thrombosis and thrombolysis · 2026Article
- Thrombosis: focus on molecular mechanisms, biomarkers and cardio-oncology.Journal of thrombosis and thrombolysis · 2026Article
- Thrombosis: focus on molecular mechanisms, biomarkers and cardio-oncology.Journal of thrombosis and thrombolysis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in cancer therapeutics, particularly targeted agents and tissue agnostic immunotherapies, have transformed care while introducing new challenges in cardiovascular safety. Although clinical guidelines have evolved, regulatory processes critical to ensuring safe innovation remain under-leveraged and often disconnected from real-world implementation. This gap is especially concerning amid federal downsizing, which has led to significant staff reductions at the United States Food and Drug Administration (FDA) and other health agencies. To meet growing needs in patient safety and therapeutic oversight, a new paradigm is emerging-one that is collaborative, adaptive, and inclusive of all stakeholders. Drug manufacturers, oncologists, cardiologists, clinical trialists, regulators, and technology developers must integrate around shared goals. Cardiovascular endpoints should be integrated into pre-new drug application (NDA) studies, with trial designs that include at-risk populations and robust cardiac monitoring. Early detection tools and mitigation strategies should be co-developed when feasible alongside therapeutics and considered part of the approval process.
Indexed as
Identifiers
42268506What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.